Meda expands presence in Asia

Meda has established an affiliate in Hong Kong. At the end of last year, Meda
opened its China affiliate based in Beijing. Meda will begin by commercializing
two of its well-established products in Hong Kong; Elidel for the treatment of
atopic dermatitis (eczema) and azelastine for the treatment of allergic rhinitis
(AR).

"We are committed to investing in new promising geographic markets and
we anticipate that our product pipeline has the potential for significant growth
in Asia", said Anders Lönner, CEO of Meda AB.
For further inquiries, please contact:

Anders Larnholt, Vice President
Corporate Development & IR ph: 46 709-458 878
MEDA AB (publ) is a leading international specialty pharma company. Meda’s
products are sold in 120 countries worldwide and the company is represented by
its own organizations in 50 countries. The Meda share is listed under Large Cap
on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit
www.meda.se.

Forward-looking Statements
This press release is not an offer
to sell or a solicitation to buy shares in Meda. This press release also
contains certain forward-looking statements with respect to certain future
events and Meda’s potential financial performance. These forward-looking
statements can be identified by the fact that they do not relate only to
historical or current facts, and may sometimes include words such as “may”,
“will”, “seek”, “anticipate”, “expect”, “estimate”, “intend”, “plan”,
“forecast”, “believe” or other words of similar meaning. These forward looking
statements reflect the current expectations on future events of the management
at the time such statements are made, but are made subject to a number of risks
and uncertainties. In the event such risks or uncertainties materialize, Meda’s
results could be materially affected. The risks and uncertainties include, but
are not limited to, risks associated with the inherent uncertainty of
pharmaceutical research and product development, manufacturing and
commercialization, the impact of competitive products, patents, legal
challenges, government regulation and approval, Meda’s ability to secure new
products for commercialization and/or development and other risks and
uncertainties detailed from time to time in Meda AB’s interim or annual reports,
prospectuses or press releases. Listeners and readers are cautioned that no
forward-looking statement is a guarantee of future performance and that actual
result could differ materially from those contained in the forward-looking
statements. Meda does not intend, nor undertakes, to update any such forward
looking statements.